Clinical Trial Highlights

H1 2023 financial highlights Total sales €1,537m +7.4% Core operating income €523m -7.9% Core operating margin¹ 34.0% -5.6% pts Core EPS² €4.73 -6.6% Free cash flow €371m +9.6% IPSEN Innovation for patient care Total-sales growth is at constant exchange rates; all other growth rates are at actual exchange rates. 1. As a ratio of core operating income to total sales. 2. Fully-diluted earnings per share. 10

View entire presentation